PT -期刊文章盟杰里米·伯吉斯AU -密涅瓦Carrasquillo盟Fanggeng邹盟生茶高盟-柯蒂斯Younkin盟Mariet艾伦AU -丹尼尔联赛盟茱莉亚骗子非盟-弗农Pankratz说道盟Asha Nair AU -苏米特Middha AU - Sooraj Maharjan AU - Thuy阮盟金伯利Malphrus AU -莎拉·林肯盟吉娜Bisceglio盟燕Asmann AU -奥托佩德拉泽盟玫瑰花蕾罗伯茨AU -约翰卢卡斯AU -格伦·史密斯盟-罗伯特Ivnik AU -玛丽Machulda AU -尼尔Graff-Radford AU -罗纳德·彼得森AU -丹尼斯·迪克森盟-史蒂文Younkin盟Nilufer tan TI -评估脑源性神经营养因子(BDNF)的影响Val66Met多态性在mRNA转录水平,阿尔茨海默病(AD)风险和认知能力(P2.163) DP - 2015年4月06 TA -神经病学PG - P2.163 VI - 84 IP - 14补充4099 - //www.ez-admanager.com/content/84/14_Supplement/P2.163.short 4100 - //www.ez-admanager.com/content/84/14_Supplement/P2.163.full所以Neurology2015 4月06;首页84 AB -目的:分析BDNF Val66Met变体在转录水平的影响,广告风险和认知功能。背景:发表的荟萃分析显示Val66Met协会增加广告风险和认知能力下降。设计/方法:Val66Met变体是使用一组Taqman试验进行验证。物流或线性回归分析与实施反是Val66Met叮铃声测试相关的基因型与广告地位在高加索病例对照系列(2951年广告,4564年控制),从我们的大脑eGWAS发表和基因表达水平(约公元200年~ 200年non-AD),以及基线认知能力的逻辑内存延迟回忆分数(MRLMD)从梅奥诊所研究衰老的参与者,分别。结果:我们观察到一个提示小脑脑源性神经营养因子mRNA水平下降的趋势相结合的一组广告,non-ADs non-ADs孤独。颞叶皮层没有一致的趋势。我们还观察到一个暗示广告风险下降的趋势(或= 0.92,p = 0.098)的运营商。这种趋势逆转,APOE-ε4该匹配以前公布的数据(或= 1.54,p = 0.13;372例和62控制)。 Diagnosis of AD occurs at a suggestively lower age in Val66Met carriers (β = -0.39, p = 0.21), a finding that reaches nominal significance in APOE-ε4 homozygotes (β = -2.16, p = 0.01). We were unable to detect an association between Val66Met status and MRLMD, regardless of APOE genotype. CONCLUSIONS: Our results suggest that within the cerebellum, decreased BDNF mRNA transcript may be mediated through the Val66Met mutation. Effects of the polymorphism on AD risk appear to be dependent on APOE-ε4 genotype, but age of AD onset appears to be earlier in carriers of the minor allele. We did not detect an association between Val66Met status and cognitive performance as measured by MRLMD.Disclosure: Dr. Burgess has nothing to disclose. Dr. Carrasquillo has nothing to disclose. Dr. Zou has nothing to disclose. Dr. Chai has nothing to disclose. Dr. Younkin has nothing to disclose. Dr. Allen has nothing to disclose. Dr. Serie has nothing to disclose. Dr. Crook has nothing to disclose. Dr. Pankratz has nothing to disclose. Dr. Nair has nothing to disclose. Dr. Middha has nothing to disclose. Dr. Maharjan has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Malphrus has nothing to disclose. Dr. Lincoln has nothing to disclose. Dr. Bisceglio has nothing to disclose. Dr. Asmann has nothing to disclose. Dr. Pedraza has nothing to disclose. Dr. Roberts has nothing to disclose. Dr. Lucas has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Ivnik has nothing to disclose. Dr. Machulda has nothing to disclose. Dr. Graff-Radford has received personal compensation for activities with Codman and Cytox as a scientific advisory board member or a consultant. Dr. Graff-Radford has received royalty payments for UpToDate. Dr. Petersen has received personal compensation for activities with Pfizer Inc. and Janssen Alzheimer's Immunotherapy. Dr. Dickson has nothing to disclose. Dr. Younkin has nothing to disclose. Dr. Taner has nothing to disclose.Tuesday, April 21 2015, 7:30 am-12:00 pm